✦ LIBER ✦

PMS23 AN ECONOMIC ANALYSIS COMPARING THREE COMBINATIONS OF TUMOR NECROSIS FACTOR-ALPHA AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS

✍ Scribed by SJ Agarwal; SS Sansgiry; ML Johnson

Book ID: 118610997
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 123 KB
Volume: 12
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)73399-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PMS28 COST-UTILITY ANALYSIS OF TUMOR NEC

PMS28 COST-UTILITY ANALYSIS OF TUMOR NECROSIS FACTOR-ALPHA INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS USING A MARKOV MODEL

✍ CM Nguyen; M Mendes; M Bounthavong; M Christopher; AP Morreale 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB

Alternative Decision Analysis Modeling i

Alternative Decision Analysis Modeling in the Economic Evaluation of Tumor Necrosis Factor Inhibitors for Rheumatoid Arthritis

✍ Khalid M. Kamal; Lesley-Ann Miller; Jan Kavookjian; Suresh Madhavan 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 137 KB

PMS56 PHARMACY REFILL PATTERNS FOR SUBCU

PMS56 PHARMACY REFILL PATTERNS FOR SUBCUTANEOUS ANTI-TUMOR NECROSIS FACTOR AGENTS USED IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN A MANAGED CARE SETTING

✍ C Carter; B Tang; A Changolkar; RS McKenzie; CT Piech 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

PMS46 Cost-Utility Analysis of Certolizu

PMS46 Cost-Utility Analysis of Certolizumab Pegol versus Alternative Tumor Necrosis Factor-Inhibitors, for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Spain

✍ R. Villoro; A. Hidalgo; B. Ferro; P. Talavera 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Modeling the 5-year cost effectiveness o

Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands

✍ Welsing, Paco M. J. ;Severens, Johan L. ;Hartman, Margriet ;van Riel, Piet L. C. 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 131 KB

B cell depletion may be more effective t

B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents

✍ Axel Finckh; Adrian Ciurea; Laure Brulhart; Diego Kyburz; Burkhard Möller; Silvi 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

## Abstract ## Objective Patients with rheumatoid arthritis (RA) in whom the response to anti–tumor necrosis factor (anti‐TNF) therapy is inadequate have several therapeutic options, such as switching to an alternative anti‐TNF agent or initiating B cell–depleting therapy with rituximab (RTX). Alt